Focus on Next-Generation Bio-threat Detection Capabilities

Smiths Detection has opened a new biolab in Hemel Hempstead in Britain, complementing the research capabilities at its Baltimore, MD facility, the company announced on 22 November. The new lab will focus developing next-generation biological threat detection capabilities, primarily for its BioFlash Biological Identifier.

BioFlash is a desktop biothreat detection system that uses CANARY technology (a cell-based biosensor), in combination with proprietary aerosol-collection techniques, to rapidly identify biothreat agents from an air sample. It can already detect biothreats such as anthrax, ricin, botulinum toxin, black plague, tularemia, smallpox, and SARS-CoV-2. The Hemel Hempstead lab will work alongside colleagues in the US to develop new detection capabilities for known and unknown biothreats.

Producing BioDiscs out of Hemel Hempstead allows the company to provide an even better service to its customers across Europe and nearby regions. The BioFlash received a CE marking in October, opening the way for the product to be sold in the EU. It was used recently at the Birmingham 2022 Commonwealth Games to support test high-security areas for the presence of SAR-CoV-2.

“The new Biolab in Hemel Hempstead is a milestone for Smiths Detection, and demonstrates our commitment to responding quickly to new and emerging threats and to supporting our customers in the region,” stated Matt Clark, VP of Technology.